<DOC>
	<DOC>NCT01522196</DOC>
	<brief_summary>The purpose of this study is to determine the effectiveness of A 001 infusion in preventing acute chest syndrome in sickle cell disease (SCD) subjects with vaso-occlusive crisis, fever, and elevated serum C-reactive protein (CRP).</brief_summary>
	<brief_title>A Study of Varespladib Infusion in Subjects With Sickle Cell Disease.</brief_title>
	<detailed_description />
	<mesh_term>Anemia, Sickle Cell</mesh_term>
	<mesh_term>Varespladib methyl</mesh_term>
	<criteria>Genotypes Hb SS, Hb SC, sickle β°thalassemia, sickle β+ thalassemia Pain consistent with vasoocclusive crisis (clinical judgment) and not attributable to other causes Serum CRP ≥5.0 mg/L at time of screening Fever defined as oral temperature ≥38.0°C at time of screening Age ≥5 years New or suspected new pulmonary infiltrate diagnosed by chest radiography Females who are nursing, pregnant or intend to become pregnant Renal dysfunction defined as a creatinine level &gt;1.2 mg/dL for subjects aged 18 or less or a creatinine level &gt;1.5 mg/dL for subjects over the age of 18 Hepatic dysfunction (alanine aminotransferase [ALT] or aspartate aminotransferase [AST] &gt;3 × upper limit of normal) Acute neurologic dysfunction Any medical condition for which transfusion may be needed imminently, and/or hemoglobin &lt;5 g/dL Red blood cell transfusion within 30 days prior to screening Parenteral or oral corticosteroid therapy (inhaled steroids acceptable) within 7 days prior to screening</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>SCD</keyword>
</DOC>